Nelarabine is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia
Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio
A one-time dose of DURVEQTIX has reduced bleeds post-treatment compared to standard of care with a median annualized bleed rate (ABR) of zero bleeds (range 0 to 9.9)
Zydus receives final approval from USFDA for its NDA Zituvimeta, extended-release tablets
Acquisition to expand Lilly's immunology pipeline with oral integrin therapies
Olverembatinib, a novel drug developed by Ascentage Pharma with support from the National Major New Drug Development program
Dyslipidemia is a critical risk factor for cardiovascular diseases
An investigational CYP11A1 Inhibitor, for the treatment of metastatic castration-resistant prostate cancer
Approval based on CAPItello-291 results which showed this combination reduced the risk of disease progression or death by 50% vs. Faslodex alone in a biomarker-altered population
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
Subscribe To Our Newsletter & Stay Updated
